ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
(MM)

(MM) (NBS)

2.25
0.00
(0.00%)
At close: 08 November 8:00AM
2.25
0.00
( 0.00% )

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
2.25
Bid
0.00
Offer
0.00
Volume
-
0.00 Day's Range 0.00
0.00 52 Week Range 0.00
Previous Close
2.25
Open
-
Last Trade
Last Trade Time
-
Average Volume (3m)
-
Financial Volume
-
VWAP
-

NBS Latest News

Diageo Terminates Heineken Partnership in South Africa

LONDON—Diageo PLC said it would terminate its partnership with Heineken NV in South Africa, as the world's largest spirits maker moves to wield more control over an increasingly important...

NeoStem Announces Plans to Change Name to Caladrius Biosciences Reflecting Transformation Into Immunotherapy Company

NEW YORK, May 29, 2015 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), a biopharmaceutical company developing novel cell-based individualized medicine therapies...

NeoStem Prices $25,000,000 Public Offering of Common Stock

NEW YORK, May 27, 2015 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), announced today the pricing of an underwritten public offering of 12,500,000 shares of common...

NeoStem Announces Proposed Public Offering of Common Stock

NEW YORK, May 27, 2015 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), announced today that it is commencing an underwritten public offering of its common stock...

NeoStem Announces Dr. Merrick Ross of MD Anderson Cancer Center as Lead Principal Investigator for Pivotal Phase 3 Trial for ...

NEW YORK, May 26, 2015 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), a biopharmaceutical company developing novel, cell-based individualized medicine therapies...

Turning Cancer Against Itself: Major Grant Advances Pioneering Melanoma Therapy at NeoStem

NEW YORK, May 21, 2015 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS) announced Thursday that it will receive one of the largest research grants of its kind to support its pioneering treatment...

NeoStem, Inc. Announces 2015 First Quarter Financial Results and Provides Corporate Update

NEW YORK, May 5, 2015 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), a biopharmaceutical company developing novel, cell-based individualized medicine therapies...

NeoStem to Present at Multiple May and June Conferences

NEW YORK, May 4, 2015 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS), a biopharmaceutical company developing novel cell-based individualized medicine therapies, announced today that the Company's...

NeoStem Announces First Patient Randomized in Pivotal Phase 3 Melanoma Immunotherapy Clinical Trial

NEW YORK, April 29, 2015 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS), a biopharmaceutical company developing novel cell-based individualized medicine therapies, announced today the...

Cryoport Supports NeoStem's Intus Study for the Treatment of Metastatic Melanoma

Cryoport Supports NeoStem's Intus Study for the Treatment of Metastatic Melanoma PR Newswire LAKE FOREST, Calif., April 29, 2015 LAKE FOREST, Calif., April 29, 2015 /PRNewswire/ -- Cryoport, Inc...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
VMARVision Marine Technologies Inc
US$ 4.45
(48.83%)
152.61k
TIVCTivic Health Systems Inc
US$ 0.3699
(42.00%)
1.95M
INODInnodata Inc
US$ 31.41
(29.05%)
169.8k
LITELumentum Holdings Inc
US$ 91.72
(24.55%)
296.43k
FIVNFive9 Inc
US$ 40.68
(23.99%)
526.17k
PRPHProPhase Labs Inc
US$ 0.99
(-30.77%)
52.33k
STKSONE Group Hospitality Inc
US$ 2.95
(-24.74%)
49.14k
MRVIMaravai LifeSciences Holdings Inc
US$ 5.9799
(-23.73%)
117.68k
ELWSEarlyworks Co Ltd
US$ 5.4091
(-19.87%)
336.44k
MDJHMDJM Ltd
US$ 0.1582
(-18.87%)
2.08M
ELABElevai Labs Inc
US$ 0.0198
(10.61%)
28.82M
TRNRInteractive Strength Inc
US$ 0.0803
(14.55%)
13.09M
LCIDLucid Group Inc
US$ 2.35
(5.86%)
11.43M
WBUYWeBuy Global Ltd
US$ 0.1946
(-14.35%)
11.29M
RIVNRivian Automotive Inc
US$ 10.17
(1.19%)
7.23M

Discussion

View Full Feed
bigsur25 bigsur25 5 minutes ago
60 Days , sixty days to get a solid position , it appears MONI has a long fuse quick flippers will get board and complain .
MONI
Bubae Bubae 5 minutes ago
Looking at the daily volume Continuation Capital probably hasn't even worked through their first 60,200,000 share tranche for fees and expenses yet. Looks like there are buyers in volume for those shares at $0.0015. I would say that there will be all you could ever want available at that price. 
BEGI
Jab44 Jab44 8 minutes ago
So predictable. The 280MM yearly sales projection was never going to be achieved, thus Foley was running out of time.
Now the $6.66 will go down.
I expect to see this case study in a Harvard Business Review someday.
RVNC
DewDiligence DewDiligence 8 minutes ago
RVNC 3Q24 results (FWIW):

https://investors.revance.com/investors/Press-Releases/news-details/2024/Revance-Reports-Third-Quarter-2024-Financial-Results-Provides-Corporate-Update/default.aspx

• 3Q24 product sales (Daxxify + dermal fillers) were $58.8M, -10% QoQ and +9%
RVNC
MiamiGent MiamiGent 10 minutes ago
Solid link. A refuge in our hectic day.
mascale mascale 10 minutes ago
Balfour Project drilling, 2022 report, is public information. The Extract at Hiru shows a Comparable transactions analysis--for the shareholder report it is likely for. Other matters appear to be public information for some length of time. It is likely that legal counsel--one or more--is involved
HIRU
Chrism0000 Chrism0000 11 minutes ago
It's about getting favors from the FDA who is run by the government money talks bull sh walks
UEEC
Zorax Zorax 12 minutes ago
Is this your proof that the company is scamming us We don't need no proof. The company will supply that for us.
Cause all the 🤥🤡🤡🤡 in the company itself.
DJT
BadaBingPebble BadaBingPebble 12 minutes ago
Holding them accountable for their own statements isn't negative. It's called accountability. I can't imagine a scenario where any investor wouldn't want that; except for you of course. Keep on begging for your 2's though....
TONR
BottomBounce BottomBounce 13 minutes ago
Silver eyes $50 in 2025 as industrial demand grows and gold-silver ratio narrows
$GLD $GDX $GDXJ $NUGT $BAR $PSLV
BAR GDX GDXJ
BottomBounce BottomBounce 13 minutes ago
Silver eyes $50 in 2025 as industrial demand grows and gold-silver ratio narrows
$GLD $GDX $GDXJ $NUGT $BAR $SLV
BAR GDX GDXJ
DR_rugby DR_rugby 13 minutes ago
The thump is getting louder

https://lindemannlaw.ch/insights/litigation-against-credit-suisse-ubs-current-status-and-legal-developments/

Sooner or later they will have to pay out these contracts, termination and close the settlements thoughout the system
GME
Idiot Mayor Idiot Mayor 13 minutes ago
Well, so much for that theory. Looks like another three months of short attacks.
ACHR
Gmenfan Gmenfan 14 minutes ago
totally agree!
DewDiligence DewDiligence 14 minutes ago
In the same section of RVNC’s 10-Q, it says that the Crown acquisition might not go through, which I consider the best-case scenario despite the uncertainty of such an outcome.
RVNC
alwayswatching1 alwayswatching1 15 minutes ago
WE ARE DOOMED
AMRN
JustGoDeep JustGoDeep 15 minutes ago
Honorable Mention, Post-Of-The-Day #2, Must Read.
BIEL
CrashOverride CrashOverride 15 minutes ago
UK was the right startup environment whilst the FDA will certainly love a nontoxic cure for cancer developed by non BP entity.
NWBO
BadaBingPebble BadaBingPebble 15 minutes ago
I'm happy to take that wager anytime any day. And, I'd be willing wager I'm sitting on substantially more shares than you.
TONR
Whalatane Whalatane 16 minutes ago
Mr Mister To the best of my knowledge , generic Renvela is the serum pho drug most prescribed to dialysis patient .
It cost about $1 per capsule and most patients need 2-3 with each meal ...so $6- $9 a day ...... max of $270 a month
Most patients don't like Renvela ( it does work
ARDX UNCY
Longstrongsilver Longstrongsilver 16 minutes ago
No idea. You’d have to ask the IR guy. You might have better luck than me as apparently he doesn’t even read what I write before replying and telling me to shut up lol. Also don’t tie your carriage to tight to my horse . My query was sincere. I’m not sure if yours are too or you are just a basher.
AZRH
JustGoDeep JustGoDeep 16 minutes ago
Honorable Mention, Post-Of-The-Day #1, Must Read.
BIEL
northam43 northam43 16 minutes ago
Report #2 October 2024 SPX Cycles

https://investorshub.advfn.com/uimage/uploads/2024/11/7/uhqig2_Completed_Cycles.PNG
meidiot meidiot 16 minutes ago
I will keep my 10 shares and keep an eye on an UNHINGED CEO.
GMPR

Your Recent History

Delayed Upgrade Clock